Anticancer Therapies – Products

Transgene and ProBioGen, announce that the companies have entered into a license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line.

Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors did not meet the primary objective of improvement.

Quell Therapeutics Ltd (“Quell” or “the Company”), and eXmoor pharma (“eXmoor”), announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell’s pipeline targeting autoimmune diseases.

Nona Biosciences, announced that it has entered into a multi-target antibody discovery collaboration with Umoja Biopharma. This collaboration leverages Nona's proprietary fully human heavy chain only antibody (HCAb) technology.

In this article, we take a look at how researchers are tackling some of the challenges that are preventing cell therapies from being more widely used, paying particular attention to cellular immunotherapies for cancer and induced pluripotent stem cel

PHC Corporation’s Biomedical Division announced the commercial launch of LiCellMo, a live cell metabolic analyzer that allows researchers to visualize metabolic changes in cell cultures.

This whitepaper explores the available technologies, key challenges and the growing impact of single-cell cloning.

This application note highlights the features of active-release beads compared to the established passive-release beads for the isolation, activation, cell expansion and desired early memory cell phenotype.

Transgene announces the publication in the Journal for ImmunoTherapy of Cancer (JITC) of a peer-reviewed article which illustrates that TG6050 induces profound immune remodeling of the tumor microenvironment in animal models.

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.